Published in Clin Liver Dis on May 01, 2009
Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol (2014) 1.46
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2014) 1.20
Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol (2010) 1.11
Role of Body Mass Index, Waist-to-Height and Waist-to-Hip Ratio in Prediction of Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract (2012) 0.96
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci (2013) 0.95
Fructose-rich diet leads to reduced aerobic capacity and to liver injury in rats. Lipids Health Dis (2012) 0.88
Impaired Gallbladder Motility and Increased Gallbladder Wall Thickness in Patients with Nonalcoholic Fatty Liver Disease. J Neurogastroenterol Motil (2016) 0.86
Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci (2016) 0.85
Intrahepatic Fat Content and Markers of Hepatic Fibrosis in Obese Children. Int J Endocrinol (2016) 0.75
Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.75
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut (2010) 2.46
Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis (2007) 2.41
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol (2012) 2.11
Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci (2012) 2.11
Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology (2005) 2.07
Health-related quality of life in patients with chronic hepatitis B. Liver Int (2007) 1.90
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (2011) 1.81
MELD fails to measure quality of life in liver transplant candidates. Liver Transpl (2005) 1.79
Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int (2008) 1.74
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med (2008) 1.72
Non-invasive markers for hepatic fibrosis. BMC Gastroenterol (2011) 1.65
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg (2005) 1.52
A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health (2009) 1.50
When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med (2010) 1.48
Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol (2007) 1.46
In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol (2012) 1.40
Resource utilization and survival among Medicare patients with advanced liver disease. Dig Dis Sci (2014) 1.40
Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol (2002) 1.34
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2007) 1.27
Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int (2007) 1.24
Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol (2010) 1.17
Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci (2007) 1.17
Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol (2010) 1.11
Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci (2004) 1.11
Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg (2005) 1.06
Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis (2008) 1.06
Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol (2005) 1.04
Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl (2008) 1.04
Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg (2009) 1.04
Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg (2006) 1.03
The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res (2008) 1.02
Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis (2007) 1.01
Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol (2009) 0.99
Adipose tissue as an endocrine organ. Clin Liver Dis (2014) 0.98
Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics (2011) 0.98
Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis (2013) 0.96
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci (2013) 0.95
Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU. Chest (2004) 0.93
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med (2004) 0.93
Recent trends in inpatient mortality and resource utilization for patients with stroke in the United States: 2005-2009. J Stroke Cerebrovasc Dis (2013) 0.90
Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg (2008) 0.89
Association of chronic liver disease with depression: a population-based study. Psychosomatics (2013) 0.88
Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2013) 0.88
Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med (2013) 0.88
Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg (2007) 0.87
Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg (2008) 0.87
Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol (2008) 0.87
Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion (2010) 0.87
Quality of life in cirrhosis. Curr Gastroenterol Rep (2013) 0.86
The impact of liver disease on health-related quality of life: a review of the literature. Curr Gastroenterol Rep (2002) 0.85
Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg (2011) 0.85
Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol (2014) 0.85
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol (2005) 0.85
Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs (2010) 0.84
Nonalcoholic fatty liver disease and bariatric surgery. Expert Rev Gastroenterol Hepatol (2012) 0.84
Validation of the chronic liver disease questionnaire in Serbian patients. World J Gastroenterol (2013) 0.83
The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int (2013) 0.83
Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn (2007) 0.83
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol (2005) 0.83
High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol (2005) 0.83
Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. J Gastroenterol Hepatol (2014) 0.83
The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology (2008) 0.82
Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr Drug Discov Technol (2007) 0.81
Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics (2007) 0.81
Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med (2004) 0.81
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care (2016) 0.81
African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol (2012) 0.80
Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci (2014) 0.80
Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liver Dis (2005) 0.80
Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol (2010) 0.80
Monoclonal and polyclonal antibodies against the HCV envelope proteins. Clin Liver Dis (2009) 0.80
Hepatic stellate cell and myofibroblast-like cell gene expression in the explanted cirrhotic livers of patients undergoing liver transplantation. Dig Dis Sci (2009) 0.79
Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int (2005) 0.79
Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Clin Drug Investig (2011) 0.79
Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history? Am J Gastroenterol (2003) 0.78
The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis (2007) 0.78
Measurement of health-related quality of life in patients with chronic liver disease. Liver Transpl (2006) 0.78
Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology (2002) 0.78
Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. Medicine (Baltimore) (2016) 0.78
Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature. Am J Gastroenterol (2010) 0.77
Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav (2012) 0.77
Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. Hepatology (2012) 0.77
Quality of life and liver transplantation in patients with polycystic liver disease. Liver Transpl (2006) 0.77
Host genetic variants in obesity-related nonalcoholic fatty liver disease. Clin Liver Dis (2013) 0.77
Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations--diagnosis and management. Am J Manag Care (2015) 0.77
Inpatient economic and mortality assessment for liver transplantation: a nationwide study of the United States data from 2005 to 2009. Transplantation (2014) 0.77
Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2015) 0.76
Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. BMC Gastroenterol (2014) 0.76
Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD. Mediators Inflamm (2013) 0.76
Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil (2014) 0.76
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). Medicine (Baltimore) (2016) 0.75
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. J Clin Gastroenterol (2017) 0.75
Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States. Emerg Infect Dis (2016) 0.75